Table 2 Diagnosis, treatment, and outcomes of CS patients with cryptococcus infection in the current study
Study’s ID | Age | Sex | UFC (ug/d) | F (µg/dL) | CS Subtype and Treatment | cryptococcus infection sites and treatment | Treatment timing for Cryptococcus infection and CS | IRIS | Outcome |
|---|---|---|---|---|---|---|---|---|---|
Kramer M [2] | 62 | F | NA | 19.3 | CD; pituitary surgery | pulmonary; AMPH-B + FU | anti-cryptococcus infection first | N | Relieved |
Kramer M [2] | 32 | F | NA | 29.8 | CD; pituitary surgery | pulmonary; AMPH-B + FU | anti-cryptococcus infection first | N | Relieved |
Yamagami, K [3] | 47 | M | NA | 73 | CD; pituitary surgery | pulmonary; Pulmonary lobectomy | anti-cryptococcus infection first | N | Relieved |
Zhao, Y [4] | 48 | F | 813.5 | 17.0 | CD; pituitary surgery | pulmonary; FLC 400Â mg/d *3Â m | anti-cryptococcus infection first | N | Relieved |
Tani, Y [5] | 75 | F | 1706 | 31.6 | EAS; pulmonary lobectomy | pulmonary; Pulmonary lobectomy | synchronous | N | Relieved |
Zhang D, [6] | 44 | M | NA | 19.7 | EAS; pulmonary lobectomy | pulmonary; Pulmonary lobectomy | synchronous | N | Relieved |
SBritton, S [7] | 24 | F | NA | NA | ACS; MET 1250Â mg/d *8Â m, Uni-ADX | CM; FU | synchronous | N | Relieved |
Cheol-In K [8] | 39 | F | 385.7 | NA | CD; KCZ & OCT | CM, skin, and blood; AMPH-B | anti-cryptococcus infection first | N | Died |
Lacativa, P G [9] | 24 | M | NA | 56.3 | CD; pituitary surgery | pulmonary; None | –- | Y | Died |
Thangakunam, B [10] | 52 | M | NA | 72 | CD; KCZ | pulmonary; AMPH-B | anti-cryptococcus infection first | N | Died |
Goto, T [11] | 85 | F | NA | 74.7 | EAS; MET | pulmonary; TMP-SMX & AmBisome | CS treatment first | Y | Died |
The present study | 66 | M | 2582.8 | 17.8 | PMAH; Uni-ADX | CM; AMPH-B and FC | CS treatment first | Y | Died |